Skip to main content

Table 3 The proportions of patients with sustained virologic response in patient sub-groups with HCV genotype 1b infection

From: Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection

 Sustained virologic response
n/N% (95% CI)
Overall3288/337197.5 (97.0–98.1)
SVR in patients who completed 12 weeks of follow-up2978/305597.5 (96.9–98.0)
SVR by treatment regimen and liver fibrosis stage
 EBR/GZR for 12 weeks
  All patients3124/320197.6 (97.0–98.1)
  APRI < 0.71882/192297.9 (97.2–98.5)
 Treatment-naive patients receiving EBR/GZR for 12 weeks
  All patients2817/288397.7 (97.1–98.2)
  APRI < 0.71708/174398.0 (97.2–98.6)
 Treatment-naive patients receiving EBR/GZR for 8 weeks
  All patients209/21895.9 (92.3–98.1)
  APRI < 0.7128/13197.7 (93.5–99.5)
 Treatment-experienced patients receiving EBR/GZR for 12 weeks
  All patients307/31896.5 (93.9–98.3)
  APRI < 0.7174/17997.2 (93.6–99.1)
 Treatment-experienced patients receiving EBR/GZR + RBV for 12 weeks
  All patients14/14100.0 (76.8–100.0)a
  APRI < 0.78/8100.0 (63.1–100.0)a
SVR by comorbidity
 Chronic kidney disease stage 4/5290/30296.0 (93.8–98.2)
 Diabetes1282/132396.9 (96.0–97.8)
 HCV/HIV co-infection50/5198.0 (94.2–100.0)
 Hepatocellular carcinoma46/4797.9 (93.7–100.0)
 History of alcohol use1834/187997.6 (96.9–98.3)
 History of drug use1527/156197.8 (97.1–98.5)
 Cirrhosis831/86096.6 (95.4–97.8)
 Platelets < 105 cells/µL121/12398.4 (96.1–100.0)
 Concomitant PPI942/96098.1 (97.3–99.0)
  1. APRI aspartate aminotransferase to platelet ratio index, EBR/GZR elbasvir/grazoprevir, HCC hepatocellular carcinoma, HCV hepatitis C virus, PPI proton pump inhibitor, RBV ribavirin, SVR sustained virologic response
  2. aOne-sided 97.5% confidence interval